Live from the NIH registry
Studies recruiting near Muskegon right now
Top 25 of 64 recruiting studies, sorted by proximity — each links to its official registry page
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
N/A
Interventional 1,956 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Urothelial Carcinoma
Phase 2
Interventional 372 participants sought
The Cancer & Hematology Centers — Norton Shores, Michigan (4.1 mi)
· Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Phase 3
Interventional 255 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Phase 3
Interventional 600 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma
Phase 3
Interventional 62 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Children's Oncology Group
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
N/A
Interventional 9,500 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 2, Phase 3
Interventional 189 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Phase 3
Interventional 486 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 2
Interventional 112 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
Phase 3
Interventional 1,670 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 2,400 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
Phase 2, Phase 3
Interventional 1,912 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Malignant Solid Neoplasm
N/A
Interventional 760 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
N/A
Observational 2,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Lung Non-Small Cell Carcinoma
Phase 2
Interventional 88 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Cutaneous Melanoma
Phase 3
Interventional 428 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Mesothelioma, Non Small Cell Lung Cancer
Phase 1
Interventional 336 participants sought
Cancer and Hematology Centers of Western Michigan — Norton Shores, Michigan (4.1 mi)
· Sponsor: Bristol-Myers Squibb
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Family Communications After Genetic Testing
Colon Adenocarcinoma, Colorectal Adenocarcinoma
N/A
Interventional 4,186 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Phase 2
Interventional 2,900 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Phase 3
Interventional 1,210 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
Phase 3
Interventional 3,960 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology